Polartechnics shares rise after major new placement
This article was originally published in Clinica
Polartechnics, an Australian company which has a cervical cancer and pre-cancer detection device in clinical trials in Europe, has raised AUS$13 million ($8.2 million) at Aus$4.40 a share from several unnamed local and overseas institutions Polartechnics said it was "an entree for major institutional investors to the company's register".
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.